Research Analysts’ Weekly Ratings Changes for Natera (NTRA)

A number of firms have modified their ratings and price targets on shares of Natera (NASDAQ: NTRA) recently:

• 1/28/2025 – Natera had its price target raised by analysts at The Goldman Sachs Group, Inc. from $160.00 to $190.00. They now have a “buy” rating on the stock.
• 1/23/2025 – Natera is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $200.00 price target on the stock.
• 1/17/2025 – Natera had its price target raised by analysts at Guggenheim from $170.00 to $200.00. They now have a “buy” rating on the stock.
• 1/10/2025 – Natera had its price target raised by analysts at Sanford C. Bernstein from $160.00 to $200.00. They now have an “outperform” rating on the stock.
• 1/3/2025 – Natera had its price target raised by analysts at Canaccord Genuity Group Inc. from $165.00 to $180.00. They now have a “buy” rating on the stock.
• 12/13/2024 – Natera had its price target raised by analysts at JPMorgan Chase & Co. from $160.00 to $200.00. They now have an “overweight” rating on the stock.

Natera Trading Down 0.6 %

Shares of NASDAQ NTRA traded down $1.02 during midday trading on Tuesday, hitting $164.24. 503,316 shares of the company traded hands, compared to its average volume of 1,348,469. Natera, Inc. has a 12-month low of $62.96 and a 12-month high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a 50-day moving average price of $166.43 and a 200 day moving average price of $136.81. The firm has a market cap of $21.68 billion, a P/E ratio of -93.32 and a beta of 1.65.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The business had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business’s revenue was up 63.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.95) earnings per share. As a group, analysts expect that Natera, Inc. will post -1.56 earnings per share for the current year.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 4,728 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $146.41, for a total transaction of $692,226.48. Following the transaction, the chief executive officer now owns 185,034 shares in the company, valued at $27,090,827.94. This represents a 2.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Solomon Moshkevich sold 24,861 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $4,101,319.17. Following the completion of the transaction, the insider now owns 140,684 shares in the company, valued at $23,208,639.48. The trade was a 15.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 243,546 shares of company stock worth $40,338,829 over the last 90 days. 7.60% of the stock is currently owned by insiders.

Institutional Trading of Natera

Institutional investors and hedge funds have recently modified their holdings of the company. Blue Trust Inc. grew its stake in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. Versant Capital Management Inc grew its stake in Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. Quarry LP grew its stake in Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares in the last quarter. Covestor Ltd grew its stake in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.